Table 1.
Demographical and clinical characteristics of the enrolled subjects
| COVID-19 | NO-COVID-19 | p value | |
|---|---|---|---|
| N (%) | 23 (56.1) | 18 (43.9) | – |
| Age median (IQR) | 45 (35–57) | 48.5 (33.25–59.5) | 0.73* |
| Male N (%) | 19 (82.6) | 11 (61.1) | 0.123§ |
| Origin N (%) | 0.014§ | ||
| West Europe | 11 (48) | 15 (83) | |
| East Europe | 0 (0) | 2 (11) | |
| Asia | 9 (39) | 0 (0) | |
| Africa | 1 (4.3) | 0 (0) | |
| South America | 2 (8.7) | 1 (6) | |
| Swab positive results N (%) | 23 (100) | 0 (0) | |
| Serology results IgM. N (%) | |||
| IgM + | 12 (52.2) | 0 (0) | |
| IgM − | 11 (47.8) | 18 (100) | |
| Serology results IgG. N (%) | |||
| IgG + | 13 (56.5) | 0 (0) | |
| IgG − | 8 (34.8) | 18 (100) | |
| IgG doubtful | 2 (8.7) | 0 (0) | |
| Severity N (%)a | |||
| Asymptomatic | 2 (8.7) | – | |
| Mild | 3 (13) | – | |
| Moderate | 11 (48) | – | |
| Severe | 5 (21.7) | – | |
| Critical | 2 (8.6) | – | |
| Cortisone N (%) | 6 (26) | – | |
| Severity of patients taking cortisone N (%) | |||
| Asymptomatic | 0 (0) | – | |
| Mild | 0 (0) | – | |
| Moderate | 2 (33) | – | |
| Severe | 3 (50) | – | |
| Critical | 1 (17) | – | |
COVID-19 Coronavirus Disease 19; N number
aWHO criteria (1)
*Mann Whitney test
§Chi-square test